Table 2.
A multivariable Cox regression analysis# of BRMS1 expression and survival in nasopharyngeal carcinoma
| |
For distant metastasis free survival |
For overall survival |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P* | HR | 95% CI | P* | |
|
Training set |
|
|
|
|
|
|
| sex (men vs. women) |
0.51 |
0.20-1.27 |
0.15 |
0.29 |
0.11-0.79 |
0.11 |
| age (> 46 vs. ≤ 46) |
1.16 |
0.55-2.46 |
0.54 |
1.11 |
0.53-2.35 |
0.72 |
| WHO type (type I vs. type II) |
0.89 |
0.20-3.99 |
0.80 |
1.31 |
0.26-5.02 |
0.81 |
| TNM stage (III, IV vs. I, II) |
3.91 |
1.35-11.29 |
0.01 |
2.59 |
0.99-6.83 |
0.04 |
| BRMS1 (low vs. high) |
4.54 |
2.11-9.76 |
0.00 |
6.56 |
2.97-14.41 |
0.00 |
| VCA-IgA (≥ 1:320 vs. < 1:320) |
0.73 |
0.26-2.03 |
0.93 |
0.41 |
0.15-1.13 |
0.21 |
| EA-IgA (≥ 1:20 vs. < 1:20) |
1.44 |
0.52-4.01 |
0.76 |
1.80 |
0.66-4.92 |
0.88 |
| AER (≥ 63% vs. < 63%) |
0.73 |
0.36-1.47 |
0.35 |
1.51 |
0.74- 2.51 |
0.07 |
|
Testing set |
|
|
|
|
|
|
| sex (men vs. women) |
0.56 |
0.22-1.38 |
0.28 |
0.76 |
0.36-1.80 |
0.62 |
| age (> 46 vs. ≤ 46) |
1.25 |
0.65-2.43 |
0.47 |
1.54 |
0.77-3.10 |
0.14 |
| WHO type (type I vs. type II) |
1.05 |
0.13-8.39 |
0.60 |
0.67 |
0.08-5.60 |
0.42 |
| TNM stage (III, IV vs. I, II) |
3.19 |
1.24-8.21 |
0.02 |
3.91 |
1.38-11.11 |
0.01 |
| BRMS1 (low vs. high) |
3.31 |
1.69-6.47 |
0.00 |
4.39 |
2.14-9.01 |
0.00 |
| VCA-IgA (≥ 1:320 vs. < 1:320) |
0.47 |
0.19-1.15 |
0.97 |
0.44 |
0.18-1.10 |
0.71 |
| EA-IgA (≥ 1:20 vs. < 1:20) |
2.78 |
1.12-6.94 |
0.19 |
2.33 |
0.91-5.98 |
0.31 |
| AER (≥ 63% vs. < 63%) |
0.57 |
0.26-1.29 |
0.32 |
1.03 |
0.49-2.19 |
0.71 |
|
Overall patient population |
|
|
|
|
|
|
| sex (men vs. women) |
0.63 |
0.34-1.18 |
0.18 |
0.57 |
0.30-1.07 |
0.15 |
| age (> 46 vs. ≤ 46) |
1.18 |
0.72-1.92 |
0.38 |
1.32 |
0.80-2.18 |
0.25 |
| WHO type (type I vs. type II) |
0.90 |
0.28-2.91 |
0.74 |
0.89 |
0.27-2.88 |
0.57 |
| TNM stage (III, IV vs. I, II) |
3.39 |
1.68-6.86 |
0.00 |
3.24 |
1.60-6.57 |
0.00 |
| BRMS1 (low vs. high) |
3.59 |
2.17-5.92 |
0.00 |
4.77 |
2.82-8.06 |
0.00 |
| VCA-IgA (≥ 1:320 vs. < 1:320) |
0.62 |
0.31-1.21 |
0.84 |
0.53 |
0.27-1.04 |
0.29 |
| EA-IgA (≥ 1:20 vs. < 1:20) |
1.91 |
0.95-3.85 |
0.16 |
1.64 |
0.82-3.29 |
0.72 |
| AER (≥ 63% vs. < 63%) | 1.20 | 0.70-2.07 | 0.36 | 1.69 | 1.00-2.86 | 0.04 |
# The variables were selected using the backward Wald stepwise selection method. * The p values were calculated using an adjusted Cox regression model. The following parameters were included as covariates in each of these models: sex (men vs. women), age (> 46 vs. ≤ 46), WHO type (type I vs. type II), TNM stage (III and IV vs. I and II), BRMS1 expression (low vs. high) VCA-IgA (≥ 1:320 vs. < 1:320), EA-IgA (≥ 1:20 vs. < 1:20) and AER (≥ 63% vs. < 63%). VCA-IgA: viral capsid antigenimmunoglobulin A; EA-IgA: early antigenimmunoglobulin A; AER: antienzyme rate (AER) of Epstein-Barr virus (EBV) DNase-specific neutralizing antibody; HR: hazard ratio; CI: confidence interval.